Skip to main content

Impact of Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer

This is a preview of subscription content, access via your institution.


  1. Khan SA, Schuetz S, Hosseini O. Primary-site local therapy for patients with de novo metastatic breast cancer: an educational review. Ann Surg Oncol. 2022;29(9):5811–20.

    Article  Google Scholar 

  2. Lane WO, Thomas SM, Blitzblau RC, et al. Surgical resection of the primary tumor in women with de novo stage IV breast cancer: contemporary practice patterns and survival analysis. Ann Surg. 2019;269(3):537–44.

    Article  Google Scholar 

  3. Thomas A, Khan SA, Chrischilles EA, et al. Initial surgery and survival in stage IV breast cancer in the United States, 1988–2011. JAMA Surg. 2016;151(5):424–31.

    Article  Google Scholar 

  4. Xiao W, Zou Y, Zheng S, et al. Primary tumor resection in stage IV breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2018;44(10):1504–12.

    Article  Google Scholar 

  5. Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol. 2013;20(9):2828–34.

    Article  Google Scholar 

  6. Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380–8.

    Article  Google Scholar 

  7. Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141–9.

    Article  Google Scholar 

  8. Soran A, Ozmen V, Ozbas S, et al. Primary surgery with systemic therapy in patients with de novo stage IV breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial. J Am Coll Surg. 2021;233(6):742-751.e745.

    Article  Google Scholar 

  9. Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE Trial. Ann Surg. 2019;269(6):1163–9.

    Article  Google Scholar 

  10. Khan SA, Zhao F, Goldstein LJ, et al. Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108). J Clin Oncol. 2022;40(9):978–87.

    Article  CAS  Google Scholar 

  11. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738–46.

    Article  CAS  Google Scholar 

  12. Anderson WF, Chen BE, Jatoi I, et al. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat. 2006;100(1):121–6.

    Article  CAS  Google Scholar 

  13. Murata T, Jinno H, Takahashi M, et al. Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence. Breast J. 2019;25(1):9–15.

    Article  CAS  Google Scholar 

  14. Khan SA, Zhao F, Goldstein L et al. Reply to B. Ulas Kahya et al. and A. Soran et al. J Clin Oncol 2022:JCO2200861.

  15. Soran A, Aytac O, Ozbas S. Locoregional therapy for intact primary tumor in de novo stage IV breast cancer. J Clin Oncol. 2022:JCO2200802.

  16. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol. 1992;21(5):837–41.

    Article  CAS  Google Scholar 

  17. Fisher LD, Dixon DO, Herson J, Frankowski RK, Hearron MS, Peace KE. Intention to treat in clinical trials. In: KE Peace, editor. Statistical issues in drug research and development. New York, NY: Marcel Dekker; 1990. p. 331–50.

    Google Scholar 

  18. Abraha I, Montedori A. Modified intention to treat reporting in randomised controlled trials: systematic review. BMJ. 2010;340:c2697.

    Article  Google Scholar 

  19. Sainani KL. Making sense of intention-to-treat. PM R. 2010;2(3):209–13.

    Article  Google Scholar 

  20. Matilde Sanchez M, Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Stat Med. 2006;25(7):1169–81.

    Article  CAS  Google Scholar 

  21. D’Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues—the encounters of academic consultants in statistics. Stat Med. 2003;22(2):169–86.

    Article  Google Scholar 

  22. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.

    Article  Google Scholar 

  23. Schumi J, Wittes JT. Through the looking glass: understanding non-inferiority. Trials. 2011;12:106.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Eleftherios A. Makris MD, PhD.

Ethics declarations

Eleftherios A. Makris and Atilla Soran have no disclosures to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Makris, E.A., Soran, A. Impact of Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer. Ann Surg Oncol 30, 1067–1071 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: